5-Fluorouracil and methotrexate combination chemotherapy: The effect of drug scheduling
article
The effect of combination chemotherapy with 5-FU and MTX administered either simultaneously or sequentially with time intervals of up to 24 hr was studied in the L1210 leukaemia, the mouse osteosarcoma C22LR and the Lewis lung carcinoma. Tumour growth delay, the number of lung metastases and lung colonies and survival times of leukaemic mice were used as parameters. Sequential treatment with MTX followed by 5-FU was the most effective antitumor schedule in the L1210 leukaemia and the osteosarcoma. This sequence of drug administration, however, also resulted in a marked weight loss and in early toxic deaths of the animals, in contrast to other schedules investigated. The implications of our findings along with an analysis of the experimental data from the literature are discussed in relation to the clinical applicability of this drug combination. Chemicals/CAS: fluorouracil, 51-21-8; methotrexate, 15475-56-6, 59-05-2, 7413-34-5; Fluorouracil, 51-21-8; Methotrexate, 59-05-2
Topics
Blood and hemopoietic systemBoneCancer chemotherapyCancer combination chemotherapyLewis carcinomaRespiratory systemBody WeightDrug Administration ScheduleDrug Therapy, CombinationFluorouracilLeukemia L1210Lung NeoplasmsMethotrexateMiceNeoplasms, ExperimentalOsteosarcomaSarcoma, ExperimentalSupport, Non-U.S. Gov't
TNO Identifier
229135
ISSN
02775379
Source
European Journal of Cancer and Clinical Oncology, 17(7), pp. 831-837.
Pages
831-837
Files
To receive the publication files, please send an e-mail request to TNO Repository.